These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 12884399)

  • 1. An enzyme-linked immunosorbent assay for host cell protein contaminants in recombinant PEGylated staphylokinase mutant SY161.
    Wan M; Wang Y; Rabideau S; Moreadith R; Schrimsher J; Conn G
    J Pharm Biomed Anal; 2002 Jun; 28(5):953-63. PubMed ID: 12039638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High yielding recombinant Staphylokinase in bacterial expression system--cloning, expression, purification and activity studies.
    Mandi N; Soorapaneni S; Rewanwar S; Kotwal P; Prasad B; Mandal G; Padmanabhan S
    Protein Expr Purif; 2009 Mar; 64(1):69-75. PubMed ID: 19000928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel preparation protocol for the expression and purification of recombinant staphylokinase.
    Ren D; Li D; Yang W; Li Y; Gou X; Liang B; Li B; Wu Q
    Biotechnol Appl Biochem; 2008 Sep; 51(Pt 1):9-13. PubMed ID: 17967161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase.
    Wang J; Hu T; Liu Y; Zhang G; Ma G; Su Z
    Anal Biochem; 2011 May; 412(1):114-6. PubMed ID: 21185800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preformulation development of recombinant pegylated staphylokinase SY161 using statistical design.
    Bedu-Addo F; Moreadith R; Advant SJ
    AAPS PharmSci; 2002; 4(4):E19. PubMed ID: 12645991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring manufacturing process yields, purity and stability of structural variants of PEGylated staphylokinase mutant SY161 by quantitative reverse-phase chromatography.
    Johnson C; Royal M; Moreadith R; Bedu-Addo F; Advant S; Wan M; Conn G
    Biomed Chromatogr; 2003 Jul; 17(5):335-44. PubMed ID: 12884399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistency and stability of recombinant fermentations.
    Wiebe ME; Builder SE
    Dev Biol Stand; 1994; 83():45-54. PubMed ID: 7883099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of biotechnological production processes.
    Werner RG; Langlouis-Gau H; Walz F; Allgaier H; Hoffmann H
    Arzneimittelforschung; 1988 Jun; 38(6):855-62. PubMed ID: 3052464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical strategies for the determination of protein modifications.
    Janis LJ; Davis GC
    Dev Biol Stand; 1994; 83():135-42. PubMed ID: 7883087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Product development issues for PEGylated proteins.
    Payne RW; Murphy BM; Manning MC
    Pharm Dev Technol; 2011 Oct; 16(5):423-40. PubMed ID: 20858059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of residual impurities and contaminants on protein stability.
    Wang W; Ignatius AA; Thakkar SV
    J Pharm Sci; 2014 May; 103(5):1315-30. PubMed ID: 24623189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic stability: an issue of product quality.
    Burns N
    Biologicals; 1993 Jun; 21(2):145-6. PubMed ID: 8297594
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.